Protalix hires Citigroup to examine sale options

Market sources see the drug developer being acquired for between $600 million and $1 billion with Pfizer the likely buyer.

Protalix Biotherapeutics Inc. (NYSE:PLX; TASE: PLX) has hired investment bank Citigroup to investigate strategic options for commercializing the company's assets or completely selling the company. Protalix is probably interested in selling either a controlling stake or the entire company.

In confriming reports Protalix said, "The company has engaged Citigroup to assist it in reviewing a broad array of product partnering, technology sharing and other strategic alternatives. There is no assurance that Protalix will undertake any such strategic alternative."

If the company is to be sold then Pfizer Inc. (NYSE: PFE) would be the logical pharmaceutical firm to acquire control of Protalix because it already has a commercialization agreement with the Israeli drug developer for its Gaucher's treatment Elylyso. However, Protalix will presumably be eager to generate competition for its acquisition as it did before reaching a commercialization deal over Elylyso. In that instance, Pfizer agreed to pay Protalix an initial sum of $60 million for the treatment that has US Food and Drug Administrative (FDA) approval.

Some market sources believe that talk of $1 billion for the acquisition of Protalix is too high. Harel Finance analyst Steven Tepper said, "It is logical for Protalix to be sold now because the products it is developing, except for Elylyso, are far from the market and it will cost significant sums to sell them, while for Elylyso peak annual sales of $180 million is reasonable, so I would give a target price of $600-700 million for the company."

On the other hand, US hedge fund Dafna Capital Management LLC (an investor in Protalix) managing member Dr. Fariba Ghodisan observes that recent deals in the pharmaceutical market reflect a large appetite by major pharmaceutical firms for the acquisition of young companies with interesting development platforms and products in advanced phases. She mentions the deal whereby Allergan acquired Map Pharmaceuticals for nearly $1 billion, even though its product was not yet approved.

She said, "I feel that a value of $1 billion is reasonable for a proven technological platform in the generics sector, especially in biogenerics, which currently very much interests the major firms."

Protalix's share price rose 20% on Wall Street this evening to $6.41, giving a market cap of $606 million.

Published by Globes [online], Israel business news - www.globes-online.com - on February 5, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

Unframe founders credit: Yossi Yarom Israeli AI enterprise platform co Unframe raises $50m

Unframe’s turnkey AI solutions enable companies to solve any enterprise AI use case at scale with fully functional, customized AI solutions for businesses in a matter of hours, rather than months.

Combatica credit: Combatica Combatica launches next-gen VR AI training platform

The Israeli company's virtual reality platform includes 50 AI generated scenarios, seven maps and even situations for operating night vision.

Shekel credit: Shutterstock Vladirina 32 Shekel volatility after US tariffs announcement

The shekel is weakening sharply against the euro, which is gaining following the unveiling of Donald Trump's tariffs plan.

Minister of Finance Bezalel Smotrich credit: Noam Moskovitz Knesset Spokesperson Treasury assesses potential damage to Israel's US exports

Israel will be charged a higher tariff on its exports to the US - its biggest export customer - than Turkey and the UAE.

Iranian flag credit: Shutterstock Why inflation haunts Iran

With a month-on-month increase of 3.3% and an annual rate of 37.1%, inflation reflects the struggles of millions of Iranians.

APM merges with lawyers from Doron, Tikotzky Kantor, Gutman credit: Eyal Merilos APM merges with 12 lawyers from Doron, Tikotzky Kantor, Gutman

With the addition of these 12 lawyers, Amit Pollak Matalon & Co. will now have 135 lawyers.

US President Donald Trump credit: Reuters Sipa USA Israel on list as Trump unveils tariffs

Relatively low reciprocal tariffs will be imposed on Israeli goods sold in the US.

Deflated unicorn credit: Shutterstock Big Tech 50 reports more huge falls in startup valuations

Israeli R&D partnership Big Tech 50 reports that an investment of $2 million in Orcam made in 2021, shrank to just $31,000 at the end of 2024.

NextFerm technologies based on yeast credit: NextFerm Food-tech co NextFerm suspends operations

The company, which produces food ingredients in yeast without genetic engineering, cannot pay its debts and is seeking a buyer.

Minister of Finance Bezalel Smotrich credit: Shlomi Yosef OECD sees recovery in growth but high inflation

The OECD Israel Economic Survey 2025 recommends that the Israeli government take several restraining measures, in order to exit the economic storm created by the war.

Dano Ben-Hur credit: Dror Sithakol Statisticians contradict BoI on impact of housing finance deals

The Central Bureau of Statistics insists the impact of 20/80 buy now pay later financing deals on the real estate market and housing prices is minimal.

Governor of the Bank of Israel Amir Yaron  credit: Government Press Office Debt fears top Bank of Israel's concerns

Most unusually, Governor of the Bank of Israel Amir Yaron's press conference last week did not focus on inflation and the impending interest rate decision.

US President Donald Trump  credit: Reuters/Leah Millis Israel moves to avoid Trump's tariffs axe

Minister of Finance Bezalel Smotrich has signed an order canceling all tariffs on imports from the US. The impact will mostly be on agricultural produce.

Forbes Rich List credit: Shutterstock Maslowski Marcin Wiz founders ranked in Forbes 2025 Rich List

There are a few dozen Israelis listed in the 2025 Forbes Real-Time Billionaires List including Wiz founders Assaf Rappaport, Yinon Costica, Roy Reznik and Ami Luttwak.

SatixFy CEO Nir Barkan credit: Ariel Barkan Canada's MDA Space to buy Israeli satcom co SatixFy

MDA Space will pay $269 million for the Israeli company, including taking on a $76 million debt and a 75% premium on SatixFy's closing price on Nasdaq yesterday.

Raising dollars credit: Shutterstock Israeli startups raised over $1b in March

Israeli privately-held tech companies have raised $2.1 billion in the first three months of 2025, according to IVC-LeumiTech, up 24% from the corresponding quarter of 2024.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018